Valeant Pharmaceuticals International (VRX) - FREE Research Report

Provencio Norma Ann who is Director at Valeant Pharmaceuticals International sold 5,000 shares at $106.70 on Nov. 5, 2013. Following this transaction, the Director owned 158,647 shares meaning that the stake was reduced by 3.06% with the 5,000 share transaction.

The shares most recently traded at $108.48, up $1.78, or 1.64% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 12-Week # shares bought: 59,532
  • 12-Week # shares sold: 9,000
  • 24-Week # shares bought: 70,472
  • 24-Week # shares sold: 15,000

The average volume for Valeant Pharmaceuticals International has been 1.2 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $36.8 billion and is part of the health care sector and drugs industry. Shares are up 83.12% year to date as of the close of trading on Tuesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 10 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Next Year's Stock Returns: 5% or 15%?

Next Year's Stock Returns: 5% or 15%?

Updating a Small Speculative Play

Updating a Small Speculative Play

Three Large-Cap Growth Stocks

Three Large-Cap Growth Stocks